Richard S. Levy
Richard S. Levy's purchase track record
Richard S. Levy has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/14/2025 | TARA | $64K | +4.2% | +69.3% | +16.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Madrigal Publishes MAESTRO-NASH Secondary Analysis Data. Madrigal Pharmaceuticals has published data from a pre-specified secondary analysis of its Phase 3 MAESTRO-NASH study in the Journal of Hepatology. The analysis evaluates how patients with altered MASH profiles respond to Rezdiffra. This update provides additional clinical context for the drug's performance in specific patient groups.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Protara Completes THRIVE-3 Trial Enrollment. Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.
Transaction History
| KNSA | ▲ Buy | Option Exercise | 403 | — | 8/1/2026 | View on chart |
| MDGL | ▲ Buy | Grant | 454 | $0 | 6/17/2026 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 2,799 | — | 5/29/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 40 | $20K | 5/22/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 320 | $163K | 5/22/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 151 | $77K | 5/22/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 610 | $312K | 5/22/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 439 | $225K | 5/22/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 40 | $21K | 5/22/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 343 | $177K | 5/22/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 657 | $339K | 5/22/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 723 | $374K | 5/22/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,497 | $775K | 5/22/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 782 | $406K | 5/22/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 80 | $42K | 5/22/2026 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 2,500 | $18K | 2/23/2026 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 683 | — | 2/1/2026 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 4,000 | $66K | 1/26/2026 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 6,000 | $99K | 11/13/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 146 | $75K | 11/13/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 919 | $474K | 11/13/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 645 | $334K | 11/13/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 835 | $433K | 11/13/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,355 | $704K | 11/13/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 308 | $160K | 11/13/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,094 | $571K | 11/13/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,434 | $750K | 11/13/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 811 | $425K | 11/13/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 153 | $80K | 11/13/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 120 | $63K | 11/13/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 200 | $106K | 11/13/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 440 | $233K | 11/13/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 40 | $21K | 11/13/2025 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 2,500 | $18K | 11/13/2025 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 1,101 | — | 7/1/2025 | View on chart |
| MDGL | ▲ Buy | Grant | 715 | $0 | 6/20/2025 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 3,173 | — | 6/5/2025 | View on chart |
| TARA | ▲ Buy | Open Market | 20,000 | $64K | 5/14/2025 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 9,470 | $616K | 4/10/2025 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 5,000 | $37K | 11/7/2024 | View on chart |
| MDGL | ▼ Sell | Open Market | 5,000 | $1.8M | 11/7/2024 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 1,303 | — | 11/7/2024 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,100 | $331K | 11/1/2024 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 5,000 | $37K | 11/1/2024 | View on chart |
| MDGL | ▼ Sell | Open Market | 300 | $91K | 11/1/2024 | View on chart |
| MDGL | ▼ Sell | Open Market | 800 | $242K | 11/1/2024 | View on chart |
| MDGL | ▼ Sell | Open Market | 2,800 | $840K | 11/1/2024 | View on chart |
| MDGL | ▲ Buy | Grant | 714 | $0 | 6/25/2024 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 4,373 | — | 6/6/2024 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 747 | — | 5/3/2024 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 5,000 | $37K | 4/1/2024 | View on chart |
| MDGL | ▼ Sell | Open Market | 4,387 | $1.1M | 4/1/2024 | View on chart |
| MDGL | ▼ Sell | Open Market | 3,900 | $1.0M | 4/1/2024 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,600 | $413K | 4/1/2024 | View on chart |
| MDGL | ▼ Sell | Open Market | 713 | $189K | 4/1/2024 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 6,000 | $666K | 4/1/2024 | View on chart |
| MDGL | ▼ Sell | Open Market | 300 | $80K | 4/1/2024 | View on chart |
| MDGL | ▼ Sell | Open Market | 100 | $26K | 4/1/2024 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 2,777 | — | 11/3/2023 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 5,000 | — | 6/29/2023 | View on chart |
| MDGL | ▲ Buy | Grant | 1,198 | $0 | 6/15/2023 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 12,489 | $1.3M | 1/17/2023 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 10,000 | $1.0M | 1/17/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 400 | $115K | 1/17/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 300 | $87K | 1/17/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 3,325 | $970K | 1/17/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 5,164 | $1.5M | 1/17/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 2,325 | $687K | 1/17/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 500 | $148K | 1/17/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 100 | $29K | 1/17/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 5,227 | $1.5M | 1/17/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 3,548 | $1.0M | 1/17/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,600 | $465K | 1/17/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Kiniksa Reports Strong Growth and Accelerating Earnings
Kiniksa Pharmaceuticals has reported earnings that are accelerating, supporting its growth narrative. Analysts note that the company’s performance shows little room for disappointment, reinforcing confidence in its business model. The company’s recent data underscores its position as a solid growth player in the pharmaceutical sector.
Kiniksa Reports Strong Growth and Accelerating Earnings. Kiniksa Pharmaceuticals has reported earnings that are accelerating, supporting its growth narrative. Analysts note that the company’s performance shows little room for disappointment, reinforcing confidence in its business model. The company’s recent data underscores its position as a solid growth player in the pharmaceutical sector.